Before you sell to, join or invest in GT Biopharma, Inc.
MentionFox check on GT Biopharma, Inc.: only 1 source on file so far (checked 4 November 2026). Run a full check before you rely on it. mentionfox.com/c/funding/gt-biopharma-inc-form-d-25000001
Check GT Biopharma, Inc. before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.
What do you want to do about GT Biopharma, Inc.?
Based on the record MentionFox holds for this company. No flag is not a clearance.
GT Biopharma, Inc. filed a Form D with the Securities and Exchange Commission on 2025-05-27.
GT Biopharma, Inc. filed a Form D notice of an exempt securities offering with the SEC on May 27, 2025. GT Biopharma, Inc. trades on Nasdaq as GTBP. The filing reports $5.95M sold. Its industry group is Biotechnology. It names Michael Breen (Chief Executive Officer), Alan Urban (Chief Financial Officer), Charles Casamento (Director) (SEC Form D, May 27, 2025).
Is this your company?
Sell to companies like GT Biopharma, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-05-27 · the record
Pitching, partnering or investing alongside them? See who really runs and owns GT Biopharma, Inc.
Free to see. No signup.
More on the people and the money behind GT Biopharma, Inc., from the filings we hold.
Biotechnology raises by companies based in California, filed in May 2025, largest first.
Get an email when GT Biopharma, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when GT Biopharma, Inc. raises, hires or launches. No email unless you switch it on.
Watch GT Biopharma, Inc. →Get the full cited report on GT Biopharma, Inc.
What the filing shows about GT Biopharma, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on GT Biopharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives GT Biopharma, Inc.'s address as 505 Montgomery Street, 10TH Floor, San Francisco, CA 94111.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for GT Biopharma, Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
GT Biopharma, Inc. is a registered filer with the SEC (CIK 109657) and has filed since 2025-03-07. 4 filings are on record, the latest on 2026-09-29.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
GT Biopharma, Inc.'s Form D of 2025-05-27 names Michael Breen, Alan Urban, Charles Casamento and 2 more as its officers, directors or promoters.
Its new offerings report $14.98M sold across 3 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 766 filings in Biotechnology, totalled by week.
Checked away from the filing. What is below does not come from the record on sec.gov.
The title and description the site itself served, answering 200, after redirecting from https://gtbiopharma.com. Not a cached copy and not the company's directory entry — what was live when we asked.
On the filing as: Executive Officer.
Michael Breen is named as Chief Executive Officer on the Form D that GT Biopharma, Inc. filed with the SEC on 27 May 2025, one of 5 people that filing names.
On the filing as: Executive Officer.
Alan Urban is named as Chief Financial Officer on the Form D that GT Biopharma, Inc. filed with the SEC on 27 May 2025, one of 5 people that filing names.
Charles Casamento is named as Director on the Form D that GT Biopharma, Inc. filed with the SEC on 27 May 2025, one of 5 people that filing names.
Hilary Kramer is named as Director on the Form D that GT Biopharma, Inc. filed with the SEC on 27 May 2025, one of 5 people that filing names.
Andrew Ritter is named as Director on the Form D that GT Biopharma, Inc. filed with the SEC on 27 May 2025, one of 5 people that filing names.
5 people named on the filing — 2 holding an executive role and 3 as directors only.
Named as of the 2025-05-27 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about GT Biopharma, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on GT Biopharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on GT Biopharma, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist GT Biopharma, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind GT Biopharma, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-11-02 (gtbiopharma.com).
Each opens in a new tab, filled in for GT Biopharma, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in San Francisco Bay Area
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/gt-biopharma-inc-form-d-25000001